First experience with BAK-free travoprost 0.004% in topical glaucoma medication.

摘要: OBJECTIVES Benzalkonium chloride (BAK)-free travoprost 0.004% (Travatan Z(®), Alcon Laboratories, Inc, Fort Worth, TX) is a new formulation that was developed with the aim of creating would maintain intraocular pressure (IOP)-lowering efficacy and have an improved overall safety profile, particularly ocular surface tolerability. METHODS Thirty newly diagnosed primary open-angle glaucoma (POAG) patients were treated BAK-free 0.004%. IOP readings recorded at baseline before initiating treatment, 4-6 weeks, after 12 weeks starting treatment. In addition, patient demographics, subjective symptoms (ie, burning, foreign-body sensation, itching, stinging), objective clinical signs such as conjunctival hyperemia collected. Subjective evaluated using four-point scale ranging from "no symptoms," "mild "moderate symptoms" to "severe symptoms." As for signs, severity evaluated. All other adverse events RESULTS provided decrease in all patients, mean 28.3 ± 2.1 mmHg 18.7 1.6 18.4 1.4 weeks. Both very few CONCLUSION The results demonstrate effective, well tolerated, safe medication POAG patients.